Small molecule recognition of c-Src via the Imatinib-binding conformation.
Small molecule recognition of c-Src via the Imatinib-binding conformation.
复制标题
DOI:
10.1016/j.chembiol.2008.09.007
复制
发表时间:
2008-10-20
影响因子:
--
通讯作者:
Shokat KM
中科院分区:
文献类型:
--
作者:
Dar AC;Lopez MS;Shokat KM
The cancer drug, Imatinib, is a selective Abl kinase inhibitor which does not inhibit the closely related kinase c-Src. This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last fifteen years. A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation effectively excluding Imatinib from its ATP pocket. This explanation of the difference in binding affinity of Imatinib for Abl versus c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the inactive conformation of c-Src with high affinity. We now report the discovery of a series of such inhibitors. We use structure-activity relationships and X-ray crystallography to confirm our findings. These studies suggest that small molecules are capable of inducing the generally unfavourable DFG-out conformation in c-Src.
登录
查看更多内容
影响因子:
9.8
作者:
Levinson NM;Kuchment O;Shen K;Young MA;Koldobskiy M;Karplus M;Cole PA;Kuriyan J
通讯作者:
Kuriyan J
影响因子:
15
作者:
Bishop, AC;Kung, CY;Liu, Y
通讯作者:
Liu, Y
影响因子:
2.7
作者:
Heron, NM;Anderson, M;Rowsell, S
通讯作者:
Rowsell, S
影响因子:
14.8
作者:
Liu, Y;Gray, NS
通讯作者:
Gray, NS
影响因子:
56.9
作者:
Papa, FR;Zhang, C;Walter, P
通讯作者:
Walter, P